中文
About Us
Corporate Overview
Sr. Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filings
News
2019
2018
2017
2016
2015
2014
Careers
2019
2018
2017
2016
2015
2014
Interpretation of Clinical Research Result of Danoprevir-based Antiviral Regimen in the Treatment of Chronic Hepatitis C Published in Chin J Infect Dis
2018-12-13
Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit
2018-11-26
Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis
2018-11-20
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
2018-11-11
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD
2018-11-05
1
2
3
»
